←
Norman Sharpless610 posts
Norman Sharpless avatar

Norman Sharpless

@nes047

Jupiter BioVentures and UNC SOM; former NCI and FDA employee. This is my personal account. COI: Jupiter, G1 Therapeutics, Karius, Nucleus, ACS

◷ Joined October 2012▧ 22 Photos and videos
U.S. Senator Bill Cassidy, M.D. avatar
⟳ Norman Sharpless retweeted
U.S. Senator Bill Cassidy, M.D.@SenBillCassidy·Nov 11

Over the last several months, I have had several frank conversations with both Dr. Overton and Mr. O’Neill about their visions, roles, and the lack of trust that exists due to broken promises and irresponsible decisions from other officials within the Administration. I appreciate their ongoing candid conversations. While I remain undecided on both of their nominations and am aware that other Republican members of the Committee are undecided as well, the Committee is moving forward with noticing their markup in the hopes of resolving their path forward one way or another this Congress.

Jay Bhattacharya, MD, PhD avatar
⟳ Norman Sharpless retweeted
Jay Bhattacharya, MD, PhD@NIHDirector_Jay·Jul 7

🙏It was my pleasure to attend the portrait unveiling ceremony that the Foundation for the National Institutes of Health (FNIH) hosted for Norman "Ned" Sharpless, M.D., on the main NIH campus in Bethesda. Dr. Sharpless served with distinction in a variety of federal science roles, most notably as director of NIH's National Cancer Institute (NCI) from 2017-2022. During his tenure, he championed investigator-initiated science, advanced childhood cancer research, and promoted big data approaches to oncology, including the Childhood Cancer Data Initiative. Beyond that, Dr. Sharpless led top research on tumor suppressor genes, cellular senescence, aging, and cancer biology. America's understanding of cancer research is far better for Dr. Sharpless's service. 🔬

Post attachment
Kelly Bolton MD PhD avatar
⟳ Norman Sharpless retweeted
Kelly Bolton MD PhD@KellyLBolton·Mar 12

Chemotherapy and ionizing radiation are known to promote clonal hematopoiesis and its progression to leukemia. By inducing temporary quiescence of hematopoietic stem cells during external stress might we mitigate CH expansion? We address this through a collaboration with @AbdelWahablab @PuZhang09980432: nature.com/articles/s41588-0…. Excited to share this and some thoughts from a recent meeting in Hiroshima which puts this work in a broader perspective.

Shreyas Kalantri, MD avatar
⟳ Norman Sharpless retweeted
Shreyas Kalantri, MD@KalantriShreyas·7 Dec 2025

🩸 ASH Plenary Spotlight CDK4/6 inhibition may mitigate chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis. Across three randomized trials, trilaciclib reduced growth of DNA damage response CH clones during chemotherapy. In murine models: • CDK4/6 inhibition before carboplatin suppressed expansion of Trp53-mutant HSPCs • Quiescence of WT HSPCs was preserved • Increased apoptosis observed in Trp53-mutant cells These data suggest that inducing HSPC quiescence with CDK4/6 inhibition may be a strategy to reduce therapy-related myeloid neoplasm risk. #ASH25 #HemeTwitter #CH #tMN @ASH_hematology

Post attachment
NIH avatar
⟳ Norman Sharpless retweeted
NIH@NIH·8 Aug 2025

This article from @KFFHealthNews is disinformation. It’s an insult to readers seeking honest reporting about NIH and misleads prospective patients who may need lifesaving care at @NIHClinicalCntr. Inpatient admissions at hospitals nationwide are in a long-term decline. But there was an abnormal drop at @NIHClinicalCntr when the Biden administration failed to return back to pre-Covid levels of clinical trials. Our data confirms this, and we’re restoring trial activities to where they should be. KFF lied to the public about @NIHClinicalCntr by cherry picking one number to fit a political agenda. We will continue to inform you when this happens.

Post attachment

NIH documents viewed by @rachanadpradhan show a pronounced decline in patients at the 200-bed NIH hospital from February through April, after the Trump administration began mass firings of federal workers and its broad crackdown on immigration. kffhealthnews.org/news/artic…

Anirban Maitra avatar
⟳ Norman Sharpless retweeted
Anirban Maitra@Aiims1742·25 Apr 2025

🤠 👉🏽 🗽 news: I will be joining @nyulangone on September 1, 2025 as Director of the GI Cancer Center & Associate Director of Translational Research at @Perlmutter_CC. I am excited to start the next chapter of the Maitra Lab in NYC & build a strong GI cancer research program.

Scott Gottlieb, MD 🇺🇸 avatar
⟳ Norman Sharpless retweeted
Scott Gottlieb, MD 🇺🇸@ScottGottliebMD·1 Apr 2025

🧵 Twenty-five years ago, it was common to hear complaints about a “drug lag”—the perception that Europeans routinely enjoyed medical advances years before their American counterparts. Through a generation of congressional actions, investments in expertise and hiring, and careful policymaking, we built the FDA into the most efficient, forward-leaning drug regulatory agency in the world—and established the U.S. as the global center of biopharmaceutical innovation. Today, the cumulative barrage on that drug-discovery enterprise, threatens to swiftly bring back those frustrating delays for American consumers, particularly affecting rare diseases and areas of significant unmet medical need.

Dr. Ron DePinho avatar
⟳ Norman Sharpless retweeted
Dr. Ron DePinho@RonDePinho·9 Feb 2025

If we want to thoughtfully reduce NIH indirect costs, we need to reduce the federal regulatory burden that causes universities to hire so many administrators to remain compliant.

Post attachment
Dr. Anthony Letai avatar
⟳ Norman Sharpless retweeted
Dr. Anthony Letai@NCIDirector·3 Dec 2024

Every year, ~90,000 teens and young adults receive a cancer diagnosis. Programs like those at @UNC_Lineberger—an NCI-Designated Comprehensive Cancer Center—help young people navigate treatment, enroll in trials, and get fertility counseling. Read more: go.nih.gov/spJyrrI

Anirban Maitra avatar
⟳ Norman Sharpless retweeted
Anirban Maitra@Aiims1742·2 Dec 2024

Novocure and its Tumor Treating Fields (TTF) Modality meets its Phase 3 trial primary endpoint of improving survival in local advanced #PancreaticCancer (LAPC). Caveats are several: - modest improvement in survival (one of those statistically significant but “is it meaningful” improvements): 14.1 months to 16.2 months. Not Gem + Erlotinib level but not that far either. - the backbone is Gem Abraxane, not FOLFIRINOX which has shown overall survival longer than the TTF combo by itself in LAPC, if the patient can tolerate the therapy. In that regard this regimen might be beneficial in an older, less fit population of LAPC patients. - I guess we should always celebrate a phase 3 success in pancreatic cancer (especially in the challenging LAPC setting) although this is not a home run.

Yara Abdou, MD, MSCR avatar
⟳ Norman Sharpless retweeted
Yara Abdou, MD, MSCR@YAbdouMD·28 Sep 2024

The rise of industry-sponsored cancer clinical trial enrollment from 2008 to 2022, now surpassing NIH-sponsored trials, highlights a shift in oncology research priorities. This trend may limit opportunities for addressing broader, patient-centered questions that are not commercially driven, potentially hindering progress in areas like prevention and survivorship. Check out our editorial @JCO_ASCO on Bridging the Gap in Cancer Clinical Trial Funding @nes047 @UNC_Lineberger ascopubs.org/doi/full/10.120…

Post attachmentPost attachment
Dr. Anthony Letai avatar
⟳ Norman Sharpless retweeted
Dr. Anthony Letai@NCIDirector·26 Sep 2024

I'm excited to announce that @NCICCHE Director Dr. Sanya Springfield will be an acting deputy director at @theNCI – in this new role, she'll be charged with broadening and strengthening our cancer health equity and inclusion efforts. #EndingCancerAsWeKnowIt for all.